UroGen Pharma
URGN
112 hedge funds and large institutions have $407M invested in UroGen Pharma in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 13 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
26% more call options, than puts
Call options by funds: $920K | Put options by funds: $728K
24% more capital invested
Capital invested by funds: $328M → $407M (+$79.4M)
8.79% more ownership
Funds ownership: 70.82% → 79.61% (+8.8%)
7% more funds holding
Funds holding: 105 → 112 (+7)
14% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$26.6M |
| 2 |
RI
RTW Investments
New York
|
+$25M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$21.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.1M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$8.49M |
| 2 |
Millennium Management
New York
|
-$6.29M |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$3.21M |
| 4 |
Cerity Partners
New York
|
-$1.44M |
| 5 |
Renaissance Technologies
New York
|
-$1.37M |
URGN Hedge Fund Activity: Q1 2024 in Review
112 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2024, worth a combined $407M — up 24% from $328M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new URGN positions and 13 closed out — a net gain of 7 holders — while 31 added to existing stakes and 36 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $26.6M. The largest seller was Morgan Stanley, cutting an estimated $8.49M.
- 112 institutional investors held UroGen Pharma (URGN) as of Q1 2024, up from 105 in Q4 2023.
- Funds reported $407M of UroGen Pharma stock for Q1 2024, up 24% quarter-over-quarter.
- 20 funds opened new UroGen Pharma positions in Q1 2024 and 13 closed out, a net change of +7 holders.
- The largest UroGen Pharma buyer in Q1 2024 was Cowen and Company, an estimated $26.6M added.
- The largest UroGen Pharma seller in Q1 2024 was Morgan Stanley, an estimated $8.49M sold.
Based on aggregated 13F filings for Q1 2024.